Boothbay Fund Management LLC acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 28,230 shares of the company's stock, valued at approximately $435,000. Boothbay Fund Management LLC owned approximately 0.19% of Inhibrx at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. bought a new position in shares of Inhibrx in the fourth quarter worth $28,000. Natixis purchased a new position in shares of Inhibrx during the fourth quarter valued at about $31,000. JPMorgan Chase & Co. lifted its position in Inhibrx by 47.8% during the fourth quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company's stock valued at $117,000 after purchasing an additional 2,457 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Inhibrx during the fourth quarter valued at about $47,000. Finally, New York State Common Retirement Fund purchased a new stake in Inhibrx during the fourth quarter valued at approximately $53,000. Institutional investors own 82.46% of the company's stock.
Inhibrx Price Performance
Shares of INBX traded down $0.38 during trading hours on Wednesday, reaching $12.06. 2,252 shares of the company traded hands, compared to its average volume of 192,339. The business has a fifty day moving average price of $12.96 and a 200-day moving average price of $13.89. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $34.75.
Inhibrx (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The business had revenue of $0.10 million for the quarter. On average, equities research analysts predict that Inhibrx, Inc. will post 104.88 EPS for the current year.
Wall Street Analyst Weigh In
Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research note on Wednesday, January 22nd.
View Our Latest Analysis on INBX
Inhibrx Company Profile
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Further Reading
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
